Dr. O'Donnell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2279 45th St
Sacramento, CA 95817Phone+1 916-734-5959Fax+1 916-703-5265
Education & Training
- University of California Davis HealthFellowship, Hematology and Medical Oncology, 1990 - 1993
- University of California Davis HealthResidency, Internal Medicine, 1987 - 1990
- Loyola University Chicago Stritch School of MedicineClass of 1987
Certifications & Licensure
- CA State Medical License 1988 - 2022
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma Start of enrollment: 2008 Jun 01
Publications & Presentations
PubMed
- 20 citationsEarly diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantationKendra Hutchinson, Patricia M. Kopko, Kathryn N. Muto, Joseph Tuscano, Robert T. O'Donnell
Transfusion. 2002-12-01 - 473 citationsProspective Evaluation of Cancer Clinical Trial Accrual Patterns: Identifying Potential Barriers to EnrollmentPrimo N. Lara, Roger Higdon, Nelson Lim, Karen Kwan, Michael Tanaka
Journal of Clinical Oncology. 2001-03-15 - 12 citationsA phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.Anthony B. El-Khoueiry, Robert T. O'Donnell, Thomas J. Semrad, Philip C. Mack, Suzette Blanchard
Cancer Chemotherapy and Pharmacology. 2018-03-08
Grant Support
- Immunoliposomal Therapy Of Non-Hodgkin'S LymphomaVeterans Affairs2012
- Phasei/Ii Clinical Trial Of Hhb22.7 Anti-Cd22 Monoclonal Antibody For LymphomaNational Cancer Institute2006–2007
- Combined Modality Radioimmunotherapy For Nonhodgkins LymphomaNational Cancer Institute1999–2002
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: